Herpes Zoster Non-Live Recombinant Vaccine (Shingrix®)

Revision Date: March 1, 2023

Rationale for Update:
- Updated to include reports of fever and shivering when co-administered with Pneumococcal 23-valent Polysaccharide (PPV23) Vaccine.

Please consult the Product Monograph¹ for further information about the vaccine.

<table>
<thead>
<tr>
<th>SHINGRIX®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
</tr>
<tr>
<td>Licensed use</td>
</tr>
<tr>
<td>Indications for use of provincially funded vaccine</td>
</tr>
<tr>
<td>Dose</td>
</tr>
<tr>
<td>Route</td>
</tr>
</tbody>
</table>
| Schedule | Primary Series:  
  - Dose 1: Day 0¹  
  - Dose 2: Two to six months later¹  
Notes:  
- Persons with active HZ should not be immunized with HZ vaccine.⁴ Vaccine may be considered at least one year after an episode of HZ disease.³  
- Shingrix® is recommended for those that have received Zostavax® prior to transplant. An interval of one year is recommended between live attenuated Herpes Zoster (Zostavax®) and Shingrix®.¹,³  
| Administration with other vaccines | Shingrix® may be administered concomitantly with, or at any time before or after, other inactivated vaccines or live vaccines protecting against a different disease.⁴  
- The vaccines should be administered at different injection sites.¹,⁴  
| Preparation | Shingrix® must be reconstituted prior to administration.¹  
- Withdraw the entire contents of the vial containing the adjuvant suspension into a sterile syringe.  
- Add the entire contents of the syringe into the vial containing the lyophilized powder. |

¹ See Immunization of Adult Solid Organ Transplant Candidates and Recipients for additional information.

² GlaxoSmithKline Inc.

³ Zostavax® is recommended for those that have received Zostavax® prior to transplant. An interval of one year is recommended between live attenuated Herpes Zoster (Zostavax®) and Shingrix®.

⁴ The vaccines should be administered at different injection sites.
### Storage and Handling
- Shake gently until the lyophilized powder is completely dissolved.
- The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.
- Store both lyophilized vial and adjuvant solution at +2°C to +8°C.\(^1\)
- Protect from light.

### Contraindications
- Known severe hypersensitivity to any component of the vaccine.\(^1\)
- Anaphylaxis to a previous dose of the vaccine.\(^2\)

### Precautions
- Shingrix® is not indicated for prevention of primary varicella infection or for the treatment of herpes zoster (HZ) or postherpetic neuralgia (PHN).\(^1\)
- There are limited data available on the use of Shingrix® in immunocompromised adults 50 years of age or older.\(^1\)
- Fever and shivering were more frequently reported when Pneumococcal Vaccine, 23-valent Polysaccharide (PPV23) vaccine was co-administered with Shingrix.\(^1\)

### Possible reactions
See Product Monograph

### Pregnancy
There are no data on the use of Shingrix® in pregnant women, therefore use with caution.\(^3\)

### Lactation
There are no data on the use of Shingrix® in breastfeeding women, therefore use with caution.\(^3\)

### Program Notes
- October 13, 2017 - licensed for use in Canada.
- September 1, 2021 – implemented for solid organ transplant recipients 18 years of age and older.
- January 28, 2022 – updated to include Health Canada approval for the prevention of herpes zoster (HZ) in individuals 18 years of age and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.
- March 1, 2023- updated to include reports of fever and shivering when co-administered with Pneumococcal 23-valent Polysaccharide (PPV23) Vaccine.
References


